Efficacy of trabectedin in metastatic solitary fibrous tumor
| Autor: | Antoine Thiery-Vuillemin, Nicolas Isambert, Xavier Pivot, Christine Fagnoni-Legat, Laura Mansi, Delphine Delroeux, Stephanie Servagi-Vernat, Lionel Aherfi, Elsa Kalbacher, Julien Pauchot, Loic Chaigneau |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Prognostic factor Chemotherapy Solitary fibrous tumor Histology Ifosfamide trabectedin business.industry medicine.medical_treatment metastatic solitary fibrous tumor Case Report medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Complete resection Primary tumor lcsh:RC254-282 Surgery Radiation therapy Oncology medicine metastatic solitary fibrous tumor trabectedin Radiology business Trabectedin medicine.drug |
| Zdroj: | Rare Tumors, Vol 3, Iss 3, Pp e29-e29 (2011) Rare Tumors |
| ISSN: | 2036-3613 2036-3605 |
| Popis: | Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m2 every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|